POINT Trial Summary: Johnston et al. randomized 4,881 patients who presented with low risk stroke or high risk TIA to either a combination of aspirin and clopidogrel or aspirin alone. Their objective was to assess the efficacy of dual antiplatelet therapy on recurrence of stroke, MI or mortality associated with ischemia. The results of POINT trial were significantly in favor of dual antiplatelet therapy when it comes to primary end point (P=0.02). However, the effect was masked by the increase in major hemorrhage risk that these patients were exposed to (P=0.01)
Full POINT trial results available at NEJM
Want to read more posts?